PSA after definitive radiotherapy for clinically localized prostate cancer.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Urologic clinics of North America

• Publication date

  1993-11-01

• Fields of study

  Medicine, Physics

• Identifiers
  PMID 7505981
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

  1993cited by this paper
• Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease.

  1992cited by this paper
• Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy.

  1992cited by this paper
• Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer.

  1992cited by this paper
• Prostate‐Specific Antigen and External Beam Radiation Therapy in Prostate Cancer

  1991cited by this paper
• Biopsy after external beam radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen levels.

  1991cited by this paper
• Prostate specific antigen levels after definitive irradiation for carcinoma of the prostate.

  1991cited by this paper
• Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy.

  1991cited by this paper
• Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

  1991cited by this paper
• Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. III. Radiation treated patients.

  1989cited by this paper
• Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer.

  1989cited by this paper
• The value of serum prostate specific antigen determinations before and after radical prostatectomy.

  1989cited by this paper
• Clinical use of prostate specific antigen in patients with prostate cancer.

  1989cited by this paper
• Combined gold seed implantation and external radiotherapy for stage B2 or C prostate cancer.

  1988cited by this paper
• Prostatic specific antigen and prostatic acid phosphatase in the monitoring and staging of patients with prostatic cancer.

  1987cited by this paper

• Radical Prostatectomy in High Risk Prostate Cancer 135 risk prostate cancer

  2017cites this paper
• Performance characteristics and relationship of PSA value/kinetics on carbon-11 acetate PET/CT imaging in biochemical relapse of prostate cancer.

  2017cites this paper
• Early Imaging Improves the Performance of C11-Acetate PET/CT for Recurrent Prostate Adenocarcinoma

  2013cites this paper
• Prostate-Specific Antigen ( PSA ) Best Practice Policy

  2013cites this paper
• Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy

  2012cites this paper
• Radical Prostatectomy in High Risk Prostate Cancer

  2011cites this paper
• Evaluation of Serum PSA in Different Storage Environments

  2010cites this paper
• 11 C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer

  2006cites this paper
• 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.

  2006cites this paper
• Undetectable prostate specific antigen at 6–12 months

  2005cites this paper
• Cryoablation of the Prostate

  2005cites this paper
• Trends in clinical trials in surgical oncology: implications for outcomes research.

  2003cites this paper
• Radiation therapy failure in prostate cancer patients: risk factors and methods of detection.

  2002cites this paper
• The impact of irregularly rising prostate-specific antigen and "impending failure" on the apparent outcome of localized prostate cancer following radiotherapy.

  2001cites this paper
• Rising PSA after a Radical Treatment

  2001cites this paper
• Prostate-specific antigen best practice policy--part II: prostate cancer staging and post-treatment follow-up.

  2001cites this paper
• Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience.

  2001cites this paper
• Local therapy for prostate-specific antigen recurrence after definitive treatment

  2001cites this paper
• [Bone scan and prostate cancer].

  2000cites this paper
• Salvage Radical Prostatectomy after Radiation Therapy and Brachytherapy

  2000cites this paper
• Matched-Pair A nalysis o f C onformal H igh-Dose-Rate Brachytherapy B oost V ersus E xternal-Beam R adiation Therapy A lone f or L ocally A dvanced P rostate C ancer

  2000cites this paper
• The management of prostate cancer in patients with a rising prostate‐specific antigen level

  2000cites this paper
• A guideline to clinical utility of prostate specific antigen.

  2000cites this paper
• Matched-pair analysis of conformal high-dose-rate brachytherapy boost versus external-beam radiation therapy alone for locally advanced prostate cancer.

  2000cites this paper
• [Management of patients with increasing PSA values after curative therapy].

  2000cites this paper
• Inherited renal cancer

  2000cites this paper
• Prostate Cancer and Combined Androgen Blockade at All Stages of Disease

  2000cites this paper
• The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer.

  1999cites this paper
• Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy

  1999cites this paper
• Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy.

  1999cites this paper
• A comprehensive review of prostate cancer brachytherapy: defining an optimal technique.

  1999cites this paper
• Detection of recurrent prostate cancer after cryosurgery.

  1998cites this paper
• Salvage surgery or salvage radiotherapy for locally recurrent prostate cancer.

  1998cites this paper
• Cell proliferation rate by MIB-1 immunohistochemistry predicts postradiation recurrence in prostatic adenocarcinomas.

  1998cites this paper
• Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature.

  1998cites this paper
• Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma.

  1998cites this paper
• [Radiotherapy of localized cancer of the prostate: current status and new strategies].

  1998cites this paper
• Evaluation and management of the man who has failed primary curative therapy for prostate cancer.

  1998cites this paper
• Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000

  1998influential citation
• The Value of Pretreatment Clinical and Biochemical Parameters in Staging and Prognostic Stratification of Patients with Newly Diagnosed Prostate Carcinoma

  1998cites this paper
• Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.

  1997cites this paper
• Focal therapy for prostate cancer 1996: maximizing outcome.

  1997cites this paper
• Management of asymptomatic rising PSA after prostatectomy or radiation therapy.

  1997cites this paper
• The PSA nadir that indicates potential cure after radiotherapy for prostate cancer.

  1997cites this paper
• Brachytherapy for clinically localized prostate cancer: results at 7- and 8-year follow-up.

  1997cites this paper
• Prostate-specific antigen after cryosurgical ablation of the prostate. Defining the appropriate response.

  1997cites this paper
• Interstitial iodine‐125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma

  1997cites this paper
• The value of pretreatment clinical and biochemical parameters in patients with newly diagnosed untreated prostate carcinoma and no indications for bone metastases on the bone scintigram

  1997cites this paper
• Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer.

  1997cites this paper
• Fifteen-year survival and recurrence rates after radiotherapy for localized prostate cancer.

  1997cites this paper
• Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels.

  1997cites this paper
• Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer.

  1996cites this paper
• Treatment options for localized recurrence of prostate cancer following radiation therapy.

  1996cites this paper
• Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control.

  1996cites this paper
• Follow-up after therapy for prostate cancer. Treating the problems and caring for the man.

  1996cites this paper
• Who is best benefited by radical prostatectomy?

  1996cites this paper
• External beam radiation therapy does not offer long-term control of prostate cancer.

  1996cites this paper
• Reference range for prostate-specific antigen levels after external beam radiation therapy for adenocarcinoma of the prostate.

  1995cites this paper
• Current controversies in the management of localized prostate cancer.

  1995cites this paper
• A guide to the interpretation of serum prostate specific antigen levels.

  1995cites this paper
• The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome.

  1995cites this paper
• [The value of prostate-specific antigen in therapy follow-up of prostatic carcinoma].

  1995cites this paper
• Surgical management of prostate cancer. Contemporary results with anatomic radical prostatectomy

  1995cites this paper
• Detailed preliminary analysis of 125iodine implantation for localized prostate cancer using percutaneous approach.

  1995cites this paper
• Original Articles: Prostate Cancer

  1995cites this paper
• Percutaneous iodine-125 seed implantation for carcinoma of the prostate.

  1995cites this paper
• Distant metastasis after radical prostatectomy in patients without an elevated serum prostate specific antigen level

  1995cites this paper
• Prostate specific antigen‐monitored combination radiotherapy for patients with prostate cancer. I‐125 implant followed by external‐beam radiation

  1995cites this paper
• Salvage radical prostatectomy: outcome measured by serum prostate specific antigen levels.

  1995cites this paper
• Radical prostatectomy and radical radiation therapy for clinical stages T1 to 2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup.

  1994cites this paper
• Follow-up after radical prostatectomy or radiation therapy for prostate cancer.

  1994cites this paper
• Patient evaluation if prostate-specific antigen becomes elevated following radical prostatectomy or radiation therapy.

  1994cites this paper
• The clinical usefulness of prostate specific antigen: update 1994.

  1994cites this paper